HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 10, October 2021 – An Inquiry into Life in the Universe       » A New Cell Factory for High-Purity DHA Production       » A New Nanoplatform With Dual-Mode Therapeutic Pathways       » Improving Breast Cancer Detection With New Liquid Biopsy Diagnosis Model       » Alginic Acid: The Secret to Building Better Bones       » Next Generation Genome Engineering With Mini CRISPR — Made Smaller to Deliver Better      
NEWS CRUNCH
Proteona awards grant to clinician-scientist for research in treatment selection of multiple myeloma
Proteona awards grant to clinician-scientist for research in treatment selection of multiple myeloma
Image attribution: www.scientificanimations.com [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)]

Singapore | 9 December 2019

Proteona Pte. Ltd. has announced the results of the inaugural Proteona Oncology Challenge, co-sponsored by NovogeneAIT. The challenge was launched in September 2019 called for abstract contributions from scientists and clinicians working to solve major clinical issues in oncology using ESCAPE? RNA-Seq single cell proteogenomic analysis services.

The final grant prize was awarded to Dr Cesar Rodrigues Valdes form the Wake Forest School of Medicine, USA. He is currently an assistant professor and a leading Haematologist based in Winston-Salem, USA.

Multiple myeloma is identified as the second most common blood cancer in the United States. Despite efforts to improve patient outcome through novel available therapies, it remains as one of the blood cancers with the poorest prognosis. Within the United States alone multiple myeloma accounts for 12, 960 deaths annually.

At present, there is no cure for multiple myeloma and patients need to be carefully monitored and managed to keep the disease in check. This in itself is no easy task as myeloma cells are highly heterogeneous, and the change of relapse is regular. The continuous need of medication also makes the blood cancer an expensive disease to manage.

One key challenge is therapy selection for treatment of multiple myeloma, particular for relapse patients. The large number of drug choices contributes to the lack of feasibility of conducting a head-to-head clinical comparison of all possible drug combinations. Resulting clinical decision-making would rely heavily on the knowledge and experience of clinicians. Data-driven tools can be extremely valuable in assisting clinicians in medical decision-making.

Dr Rodrigeuz Valdes's proposal aims to tackle the issue of treatment selection for multiple myeloma. By applying single-cell proteogenomics in his patient-derived 3D organoid model, he will compare cell populations in response to multiple drugs, identifying the difference in protein and gene expression patterns. These studies will help to elucidate the mechanism of drug sensitivity, and potentially help to choose the suitable therapeutic combination for each patient.

"We are excited about combining Proteona's single-cell proteogenomic analysis with our patient-derived organoid screening platform," said Dr Rodriguez Valdes. "Our ambition is to develop a predictive, validated test that will facilitate clinical decision-making and improve the outcome of multiple myeloma treatment. This grant will help us to move closer to that goal."

Since its launch in September 2019, the Challenge has received numerous submissions from all over the world from different fields of oncology.

"It has been a difficult decision to make," said Proteona CEO, Andreas Schmidt. "We have seen many excellent, high quality projects, each addressing an important clinical question. We had to take into consideration different factors including availability of samples, expected time to clinical impact, and feasibility. We actually decided to expand the original grant and to give out additional awards to recognize some of the best proposals. We are excited about working with these top teams, and use the in-depth information from single cell proteogenomic analysis to bring their projects closer to clinical application."

Other award winners of the Proteona Oncology Challenge include:

Runner-up: Dr Sanjay de Mel - National University Cancer Institute, Singapore

Finalists:
Dr Nicholas Gascoigne – National University of Singapore, Singapore
Dr Steve Bilodeau – Université Laval, Canada
Dr Aaron Tan – National Cancer Centre Singapore, Singapore

FORTHCOMING ISSUE  
Launch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific
NEWS CRUNCH  
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
news A New Approach for Effective Gout Treatment
news TechInnovation Returns from 28 to 30 September 2021
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy